New U.S. Patent 6,982,089 Issued - Describing a Novel Biotechnology Approach to Alzheimer's Disease

New U.S. patent 6,982,089, describing perispinal administration of biological TNF-alpha modulators for certain neurological disorders, issued on January 3, 2006, awarded to Edward Tobinick, MD, Los Angeles, California.

Los Angeles, CA (PRWEB) February 20, 2006 -- U.S. patent 6,982,089, awarded to Edward Tobinick, MD, issued on January 3, 2006. This new patent describes novel methods for Alzheimer's Disease using molecules developed through recombinant DNA technology. The patented methods involve the perispinal use of certain biologic inhibitors of TNF-alpha, including etanercept, certolizumab pegol (CDP 870), and others, for clinical disorders in which neurological inflammation is thought to play a significant role.

TNF-alpha is a proinflammatory cytokine, a protein which is involved in the initiation and amplification of the immune response which causes inflammation in a variety of organ systems, including the brain. This patent also includes claims involving the perispinal use of certain biologic TNF inhibitors, including adalimumab and certolizumab pegol, for disorders involving neurologic pain and inflammation, including post-herpetic neuralgia, reflex sympathetic dystrophy, other forms of neuropathic pain, fibromyalgia, low back pain, and vertebral disc disease, all clinical conditions with unmet medical need.

Note: Edward Tobinick, MD is the Medical Director of Institute Research Associates, a [private Medical Group, Inc., 100 UCLA Medical Plaza, Suites 205-210, Los Angeles, California 90095, (310) 824-6191. This press release describes patent claims and should not be interpreted as a treatment recommendation, which it is not.

# # #